

Robert J Glynn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2729005/publications.pdf>

Version: 2024-02-01

272
papers

44,641
citations

3525

90
h-index

2032

205
g-index

281
all docs

281
docs citations

281
times ranked

43651
citing authors

#	ARTICLE	IF	CITATIONS
1	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2022, 118, 897-903.	1.8	17
2	Tutorial on Biostatistics: Receiver-Operating Characteristic (ROC) Analysis for Correlated Eye Data. <i>Ophthalmic Epidemiology</i> , 2022, 29, 117-127.	0.8	8
3	Racial and Socioeconomic Differences in Eye Care Utilization among Medicare Beneficiaries with Glaucoma. <i>Ophthalmology</i> , 2022, 129, 397-405.	2.5	42
4	Evolving channeling in prescribing SGLT2 inhibitors as first-line treatment for type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 566-576.	0.9	2
5	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. <i>Annals of Internal Medicine</i> , 2022, 175, 927-937.	2.0	20
6	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 692-703.	1.4	19
7	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. <i>Circulation</i> , 2021, 143, 770-779.	1.6	47
8	Age-related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B). <i>Acta Ophthalmologica</i> , 2021, 99, e285-e287.	0.6	1
9	Tutorial on Biostatistics: Longitudinal Analysis of Correlated Continuous Eye Data. <i>Ophthalmic Epidemiology</i> , 2021, 28, 3-20.	0.8	20
10	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. <i>Circulation</i> , 2021, 143, 1002-1013.	1.6	174
11	Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. <i>Implementation Science</i> , 2021, 16, 9.	2.5	14
12	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 816-828.	2.3	29
13	Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study. <i>American Journal of Epidemiology</i> , 2021, 190, 1659-1670.	1.6	31
14	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. <i>Journal of Cancer Prevention</i> , 2021, 26, 71-82.	0.8	4
15	The probability of sudden unexpected death in epilepsy given postictal prone position. <i>Epilepsy and Behavior</i> , 2021, 116, 107775.	0.9	3
16	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. <i>JAMA Cardiology</i> , 2021, 6, 437.	3.0	82
17	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. <i>Diabetes Care</i> , 2021, 44, 1774-1782.	4.3	24
18	Coprescription of Opioids With Other Medications and Risk of Opioid Overdose. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1011-1017.	2.3	16

#	ARTICLE	IF	CITATIONS
19	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3197-3207.	3.0	11
20	Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2021, , .	2.3	7
21	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1214-1223.	2.0	48
22	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	2.0	52
23	The neutrophilâ€“lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. <i>European Heart Journal</i> , 2021, 42, 896-903.	1.0	152
24	Using propensity scores to estimate effects of treatment initiation decisions: State of the science. <i>Statistics in Medicine</i> , 2021, 40, 1718-1735.	0.8	50
25	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. <i>Rheumatology</i> , 2021, 60, 2963-2968.	0.9	3
26	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and highâ€“sensitivity Câ€“reactive protein in <sc>CANTOS</sc>. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3
27	Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1120-1125.	1.7	82
28	Nonrandomized Realâ€“World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 817-826.	2.3	76
29	Characteristics of atypical postradiation vascular proliferation: A retrospective review of 193 patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1447-1450.	0.6	7
30	Effects of Interleukin-1 ^{Î²} Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk. <i>Hypertension</i> , 2020, 75, 477-482.	1.3	69
31	Adverse Effects of Lowâ€“Dose Methotrexate in a Randomized Doubleâ€“Blind Placeboâ€“Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 697-704.	0.9	18
32	Effects of Interleukin-1 ^{Î²} Inhibition on Incident Anemia. <i>Annals of Internal Medicine</i> , 2020, 172, 523.	2.0	37
33	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	2.0	126
34	Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107704.	1.2	15
35	Calculating Sensitivity, Specificity, and Predictive Values for Correlated Eye Data. , 2020, 61, 29.		34
36	Plasma <sc>NT1</sc> Tau is a Specific and Early Marker of Alzheimer's Disease. <i>Annals of Neurology</i> , 2020, 88, 878-892.	2.8	24

#	ARTICLE	IF	CITATIONS
37	Response by Eberly et al to Letter Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center". <i>Circulation: Heart Failure</i> , 2020, 13, e007193.	1.6	3
38	Dynamics of plasma biomarkers in Down syndrome: the relative levels of A β 42 decrease with age, whereas NT1 tau and NfL increase. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 27.	3.0	20
39	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. <i>European Heart Journal</i> , 2020, 41, 2952-2961.	1.0	72
40	<p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 607-616.	1.5	15
41	<p>External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 133-141.	1.5	18
42	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 735-737.	2.3	27
43	Improving measurement of binary covariates in claims data: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1093-1100.	0.9	1
44	Incidence of venous thromboembolism following initiation of non-steroidal anti-inflammatory drugs in U.S. women. <i>Rheumatology</i> , 2020, 59, 2502-2511.	0.9	2
45	Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
46	Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1271-1276.	1.7	130
47	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. <i>Drug Safety</i> , 2019, 42, 1355-1363.	1.4	1
48	Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1290-1298.	0.9	19
49	Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1899.	3.8	77
50	Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. <i>Circulation: Heart Failure</i> , 2019, 12, e006214.	1.6	100
51	A Case-â€Crossoverâ€-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 238-244.	2.3	17
52	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 934-941.	0.9	6
53	Comparison of Questionnaire-Based Breast Cancer Prediction Models in the Nurses' Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1187-1194.	1.1	12
54	Group IIA Secretary Phospholipase A ₂ , Vascular Inflammation, and Incident Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1182-1190.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Assessment of Employee Susceptibility to Phishing Attacks at US Health Care Institutions. JAMA Network Open, 2019, 2, e190393.	2.8	39
56	Evaluation of a mandatory phishing training program for high-risk employees at a US healthcare system. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 547-552.	2.2	41
57	Quantifying bias reduction with fixed duration versus all available covariate assessment periods. Pharmacoepidemiology and Drug Safety, 2019, 28, 665-670.	0.9	10
58	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. BMJ Quality and Safety, 2019, 28, 835-842.	1.8	13
59	COMPARATIVE PERFORMANCE OF FOUR CLAIMS-BASED FRAILTY MEASURES IN THE UNITED STATES MEDICARE DATA. Innovation in Aging, 2019, 3, S684-S685.	0.0	1
60	Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiology and Drug Safety, 2019, 28, 305-314.	0.9	1
61	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.	13.9	886
62	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384
63	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clinical Pharmacology and Therapeutics, 2019, 105, 867-877.	2.3	112
64	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. American Journal of Epidemiology, 2019, 188, 609-616.	1.6	25
65	Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Washington, DC), 2019, 7, 27.	2.0	2
66	Classifying medical histories in US Medicare beneficiaries using fixed vs all available look-back approaches. Pharmacoepidemiology and Drug Safety, 2018, 27, 771-780.	0.9	17
67	Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 980-987.	1.7	303
68	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. Journal of Comparative Effectiveness Research, 2018, 7, 57-66.	0.6	2
69	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ: British Medical Journal, 2018, 360, k119.	2.4	132
70	Comparing Approaches to Measure Frailty in Medicare Data: Deficit-Accumulation Frailty Index Versus Phenotypic Frailty. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 989-990.	1.7	8
71	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. Pharmacoepidemiology and Drug Safety, 2018, 27, 567-569.	0.9	11
72	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 2018, 71, 2392-2401.	1.2	236

#	ARTICLE	IF	CITATIONS
73	Parity, Job Strain, and Cardiovascular Risk in the Women's Health Study. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	5
74	Tutorial on Biostatistics: Statistical Analysis for Correlated Binary Eye Data. <i>Ophthalmic Epidemiology</i> , 2018, 25, 1-12.	0.8	79
75	Inflammation, venous thromboembolism, and what we can do about it. <i>European Heart Journal</i> , 2018, 39, 3615-3617.	1.0	6
76	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 899-905.	2.3	40
77	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with three-group matching weights. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 182-190.	0.9	13
78	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 319-328.	6.3	628
79	A multicomponent frailty intervention for socioeconomically vulnerable older adults: a designed-delay study. <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 1799-1814.	1.3	45
80	Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2018, 74, 11-17.	0.8	6
81	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	1.2	276
82	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. <i>Health Affairs</i> , 2018, 37, 125-133.	2.5	41
83	Relationship of Interleukin-1 β Blockade With Incident Gout and Serum Uric Acid Levels. <i>Annals of Internal Medicine</i> , 2018, 169, 535.	2.0	74
84	Inhibition of Interleukin-1 β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2405-2414.	1.2	186
85	Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research. <i>Epidemiology</i> , 2018, 29, 356-363.	1.2	41
86	Real-World Data Analytics Fit for Regulatory Decision-Making. <i>American Journal of Law and Medicine</i> , 2018, 44, 197-217.	0.5	18
87	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). <i>European Heart Journal</i> , 2018, 39, 3499-3507.	1.0	375
88	Risk of Incident Osteoarthritis of the Hand in Statin Initiators: A Sequential Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1795-1805.	1.5	14
89	Tutorial on Biostatistics: Linear Regression Analysis of Continuous Correlated Eye Data. <i>Ophthalmic Epidemiology</i> , 2017, 24, 130-140.	0.8	108
90	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. <i>Clinical Chemistry</i> , 2017, 63, 870-879.	1.5	74

#	ARTICLE	IF	CITATIONS
91	Estimation of rank correlation for clustered data. <i>Statistics in Medicine</i> , 2017, 36, 2163-2186.	0.8	10
92	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. <i>Circulation</i> , 2017, 135, 2494-2504.	1.6	180
93	A Comprehensive Model of Colorectal Cancer by Risk Factor Status and Subsite Using Data From the Nurses' Health Study. <i>American Journal of Epidemiology</i> , 2017, 185, 224-237.	1.6	39
94	Disease associations with isolated elevations of each of the four IgG subclasses. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 276-280.	1.6	29
95	Primary Prevention With Statin Therapy in the Elderly. <i>Circulation</i> , 2017, 135, 1979-1981.	1.6	97
96	Matching Weights to Simultaneously Compare Three Treatment Groups. <i>Epidemiology</i> , 2017, 28, 387-395.	1.2	97
97	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
98	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
99	Association of tobacco use and cessation with coronary atherosclerosis. <i>Atherosclerosis</i> , 2017, 257, 201-207.	0.4	25
100	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2017, 390, 1833-1842.	6.3	948
101	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
102	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	98
103	Editorial: Use of Propensity Scores To Design Observational Comparative Effectiveness Studies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	6
104	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	61
105	Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 215-223.	1.1	7
106	The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. <i>American Journal of Epidemiology</i> , 2017, 185, 842-852.	1.6	15
107	Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. <i>Annals of Internal Medicine</i> , 2017, 166, 81.	2.0	45
108	Benzodiazepines and risk of all cause mortality in adults: cohort study. <i>BMJ: British Medical Journal</i> , 2017, 358, j2941.	2.4	60

#	ARTICLE	IF	CITATIONS
109	Prediction Score for Anticoagulation Control Quality Among Older Adults. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	26
110	Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	44
111	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. <i>Journal of Clinical Epidemiology</i> , 2016, 76, 200-208.	2.4	21
112	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <i>American Heart Journal</i> , 2016, 178, 135-144.	1.2	58
113	Folic Acid, Vitamin B ₆ , and Vitamin B ₁₂ in Combination and Age-Related Cataract in a Randomized Trial of Women. <i>Ophthalmic Epidemiology</i> , 2016, 23, 32-39.	0.8	23
114	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 136.	3.0	53
115	Multivitamin Use and the Risk of Cardiovascular Disease in Men. <i>Journal of Nutrition</i> , 2016, 146, 1235-1240.	1.3	19
116	A Review of Disease Risk Scores and Their Application in Pharmacoepidemiology. <i>Current Epidemiology Reports</i> , 2016, 3, 277-284.	1.1	10
117	Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. <i>BMJ, The</i> , 2016, 353, i2607.	3.0	28
118	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. <i>American Journal of Hypertension</i> , 2016, 29, 1117-1124.	1.0	13
119	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. <i>American Journal of Epidemiology</i> , 2016, 183, 949-957.	1.6	24
120	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. <i>Emerging Themes in Epidemiology</i> , 2016, 13, 5.	1.2	17
121	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. <i>Circulation Research</i> , 2016, 118, 1106-1115.	2.0	97
122	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. <i>PLoS ONE</i> , 2016, 11, e0165615.	1.1	31
123	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 653.e7-653.e16.	0.6	75
124	Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. <i>International Journal of Cancer</i> , 2015, 137, 625-637.	2.3	60
125	Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. <i>American Journal of Epidemiology</i> , 2015, 182, 651-659.	1.6	50
126	Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs. <i>American Journal of Medicine</i> , 2015, 128, 539.e7-539.e17.	0.6	30

#	ARTICLE	IF	CITATIONS
127	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. <i>JAMA Ophthalmology</i> , 2015, 133, 17.	1.4	38
128	Statin Therapy and Risk of Fracture. <i>JAMA Internal Medicine</i> , 2015, 175, 171.	2.6	53
129	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo. <i>Circulation</i> , 2015, 132, 2220-2229.	1.6	101
130	Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men. <i>Journal of the American Heart Association</i> , 2015, 4, e002073.	1.6	26
131	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1360-1367.	0.5	108
132	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1968-1975.	0.5	82
133	Time-Dependent Propensity Score for Assessing the Effect of Vaccine Exposure on Pregnancy Outcomes through Pregnancy Exposure Cohort Studies. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 3074-3085.	1.2	9
134	Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 915-923.	2.2	83
135	Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. <i>Acta Diabetologica</i> , 2014, 51, 1015-1023.	1.2	35
136	Studies with Many Covariates and Few Outcomes. <i>Epidemiology</i> , 2014, 25, 268-278.	1.2	57
137	Predisposing Factors Associated With Development of Persistent Compared With Paroxysmal Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2014, 3, e000916.	1.6	69
138	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 372-381.	0.3	26
139	Effects of Multivitamin Supplement on Cataract and Age-Related Macular Degeneration in a Randomized Trial of Male Physicians. <i>Ophthalmology</i> , 2014, 121, 525-534.	2.5	60
140	Reducing Bias Amplification in the Presence of Unmeasured Confounding through Out-of-Sample Estimation Strategies for the Disease Risk Score. <i>Journal of Causal Inference</i> , 2014, 2, 131-146.	0.5	17
141	Model Misspecification When Excluding Instrumental Variables from PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment. <i>Epidemiologic Methods</i> , 2014, 3, 83-96.	0.8	1
142	Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. <i>International Journal of Cardiology</i> , 2013, 168, 1894-1899.	0.8	32
143	Breast Cancer Risk Prediction with Heterogeneous Risk Profiles According to Breast Cancer Tumor Markers. <i>American Journal of Epidemiology</i> , 2013, 178, 296-308.	1.6	61
144	Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 810-818.	0.9	50

#	ARTICLE	IF	CITATIONS
145	A Randomized Study of How Physicians Interpret Research Funding Disclosures. <i>New England Journal of Medicine</i> , 2012, 367, 1119-1127.	13.9	165
146	The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. <i>Cmaj</i> , 2012, 184, E367-E372.	0.9	59
147	Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. <i>Lancet, The</i> , 2012, 380, 565-571.	6.3	691
148	Regression Methods when the Eye is the Unit of Analysis. <i>Ophthalmic Epidemiology</i> , 2012, 19, 159-165.	0.8	108
149	On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1521-1528.	1.2	90
150	Role of disease risk scores in comparative effectiveness research with emerging therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 138-147.	0.9	87
151	The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels. <i>Journal of the American College of Cardiology</i> , 2011, 57, 784-791.	1.2	38
152	The Association between Statin use and Outcomes Potentially Attributable to an Unhealthy Lifestyle in Older Adults. <i>Value in Health</i> , 2011, 14, 513-520.	0.1	55
153	Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. <i>American Heart Journal</i> , 2011, 162, 106-114.e2.	1.2	40
154	A combined comorbidity score predicted mortality in elderly patients better than existing scores. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 749-759.	2.4	728
155	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 551-559.	0.9	111
156	Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1483-1487.	1.0	7
157	Risk Factors for Mortality in the Nurses' Health Study: A Competing Risks Analysis. <i>American Journal of Epidemiology</i> , 2011, 173, 319-329.	1.6	130
158	Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 312-317.	5.1	48
159	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. <i>American Journal of Epidemiology</i> , 2011, 174, 1213-1222.	1.6	205
160	Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. <i>American Journal of Epidemiology</i> , 2011, 173, 1404-1413.	1.6	149
161	Confounding Control in Healthcare Database Research. <i>Medical Care</i> , 2010, 48, S114-S120.	1.1	291
162	Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial. <i>Annals of Internal Medicine</i> , 2010, 152, 488.	2.0	198

#	ARTICLE	IF	CITATIONS
163	Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). <i>American Journal of Cardiology</i> , 2010, 106, 204-209.	0.7	136
164	The JUPITER Trial: Responding to the Critics. <i>American Journal of Cardiology</i> , 2010, 106, 1351-1356.	0.7	29
165	Response to Letter Regarding Article, "Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women". <i>Circulation</i> , 2010, 121, .	1.6	2
166	Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 447-452.	0.9	52
167	Promises and Limitations of Mendelian Randomization for Evaluation of Biomarkers. <i>Clinical Chemistry</i> , 2010, 56, 388-390.	1.5	13
168	The Comparative Safety of Analgesics in Older Adults With Arthritis. <i>Archives of Internal Medicine</i> , 2010, 170, 1968.	4.3	348
169	Burden of smoking on cause-specific mortality: application to the Nurses' Health Study. <i>Tobacco Control</i> , 2010, 19, 248-254.	1.8	61
170	Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 341, c5702-c5702.	2.4	299
171	Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study. <i>American Journal of Epidemiology</i> , 2010, 172, 843-854.	1.6	343
172	Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1266-1273.	1.2	191
173	Vitamin E and Age-Related Macular Degeneration in a Randomized Trial of Women. <i>Ophthalmology</i> , 2010, 117, 1163-1168.	2.5	35
174	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet, The</i> , 2010, 376, 333-339.	6.3	221
175	Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 465-469.	0.5	5
176	Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. <i>Swiss Medical Weekly</i> , 2010, 140, 202-8.	0.8	10
177	Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 616-623.	0.9	128
178	A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2009, 360, 1851-1861.	13.9	657
179	Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study. <i>Clinical Chemistry</i> , 2009, 55, 305-312.	1.5	82
180	Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women. <i>Circulation</i> , 2009, 119, 2146-2152.	1.6	285

#	ARTICLE	IF	CITATIONS
181	An Evaluation of Candidate Genes of Inflammation and Thrombosis in Relation to the Risk of Venous Thromboembolism. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 57-62.	5.1	36
182	Statin Adherence and Risk of Accidents. <i>Circulation</i> , 2009, 119, 2051-2057.	1.6	217
183	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. <i>American Journal of Epidemiology</i> , 2009, 169, 909-917.	1.6	71
184	Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. <i>European Heart Journal</i> , 2009, 30, 1378-1384.	1.0	75
185	High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. <i>Epidemiology</i> , 2009, 20, 512-522.	1.2	870
186	Evaluation of Risk Factors for Cataract Types in a Competing Risks Framework. <i>Ophthalmic Epidemiology</i> , 2009, 16, 98-106.	0.8	42
187	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1226-1232.	2.4	146
188	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. <i>Lancet</i> , The, 2009, 373, 1175-1182.	6.3	886
189	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply. <i>Lancet</i> , The, 2009, 374, 26-27.	6.3	2
190	Methodological issues affecting estimates of bleeding risks and consequences after venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 797-8.	1.8	1
191	Evaluating uses of data mining techniques in propensity score estimation: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 546-555.	0.9	195
192	Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1247-1254.	1.2	164
193	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>New England Journal of Medicine</i> , 2008, 359, 2195-2207.	13.9	5,712
194	Response to Letter Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study". <i>Circulation</i> , 2008, 117, .	1.6	0
195	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. <i>Circulation</i> , 2007, 115, 27-33.	1.6	145
196	Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2007, 335, 432.	2.4	94
197	Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism. <i>Circulation</i> , 2007, 116, 1497-1503.	1.6	117
198	Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension. <i>Hypertension</i> , 2007, 50, 1114-1119.	1.3	33

#	ARTICLE	IF	CITATIONS
199	Sturmer et al. Respond to "Propensity Score Methods in Epidemiology". American Journal of Epidemiology, 2007, 165, 1122-1123.	1.6	14
200	Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism. Annals of Internal Medicine, 2007, 147, 525.	2.0	66
201	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. Medical Care, 2007, 45, S131-S142.	1.1	228
202	Design of Cluster-Randomized Trials of Quality Improvement Interventions Aimed at Medical Care Providers. Medical Care, 2007, 45, S38-S43.	1.1	62
203	Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. Medical Care, 2007, 45, S158-S165.	1.1	68
204	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. European Heart Journal, 2007, 28, 2937-2943.	1.0	153
205	Interval estimation for rank correlation coefficients based on the probit transformation with extension to measurement error correction of correlated ranked data. Statistics in Medicine, 2007, 26, 633-646.	0.8	44
206	Ten-Year Trends of Cardiovascular Drug Use After Myocardial Infarction Among Community-Dwelling Persons ≥ 65 Years of Age. American Journal of Cardiology, 2007, 100, 1061-1067.	0.7	45
207	Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. American Journal of Cardiology, 2007, 100, 1659-1664.	0.7	113
208	Awareness, Accuracy, and Predictive Validity of Self-Reported Cholesterol in Women. Journal of General Internal Medicine, 2007, 22, 606-613.	1.3	29
209	A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. Journal of Clinical Epidemiology, 2006, 59, 437.e1-437.e24.	2.4	557
210	Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. Journal of Clinical Epidemiology, 2006, 59, 18-25.	2.4	34
211	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. Journal of Clinical Epidemiology, 2006, 59, 819-828.	2.4	115
212	Indications for Propensity Scores and Review of their Use in Pharmacoepidemiology. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 253-259.	1.2	474
213	Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect. American Journal of Epidemiology, 2006, 163, 262-270.	1.6	615
214	Variable Selection for Propensity Score Models. American Journal of Epidemiology, 2006, 163, 1149-1156.	1.6	1,618
215	Commentary: Genes as instruments for evaluation of markers and causes. International Journal of Epidemiology, 2006, 35, 932-934.	0.9	10
216	Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information. Epidemiology, 2005, 16, 17-24.	1.2	101

#	ARTICLE	IF	CITATIONS
217	Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration. American Journal of Epidemiology, 2005, 162, 279-289.	1.6	185
218	Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. American Journal of Epidemiology, 2005, 161, 891-898.	1.6	155
219	JNC 7 Category and Risk of Cardiovascular Death in Men: Are There Differences by Age?. The American Journal of Geriatric Cardiology, 2005, 14, 126-133.	0.7	17
220	Comparison of Risk Factors for the Competing Risks of Coronary Heart Disease, Stroke, and Venous Thromboembolism. American Journal of Epidemiology, 2005, 162, 975-982.	1.6	338
221	A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. Journal of Clinical Epidemiology, 2005, 58, 98-102.	2.4	62
222	Blood Pressure and Risk of Secondary Cardiovascular Events in Women. Circulation, 2004, 109, 1623-1629.	1.6	42
223	Effect of physical activity on serum C-reactive protein. American Journal of Cardiology, 2004, 93, 221-225.	0.7	151
224	C-Reactive protein levels among women of various ethnic groups living in the United States (from the Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	231
225	Multiple imputation to estimate the association between eyes in disease progression with interval-censored data. Statistics in Medicine, 2004, 23, 3307-3318.	0.8	10
226	Use of Covariates and Survey Wave to Adjust for Nonresponse. Biometrical Journal, 2004, 46, 579-588.	0.6	7
227	Methods to evaluate risks for composite end points and their individual components. Journal of Clinical Epidemiology, 2004, 57, 113-122.	2.4	63
228	Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. American Heart Journal, 2004, 148, 99-104.	1.2	489
229	Improved Comorbidity Adjustment for Predicting Mortality in Medicare Populations. Health Services Research, 2003, 38, 1103-1120.	1.0	273
230	Alcohol Consumption and Plasma Concentration of C-Reactive Protein. Circulation, 2003, 107, 443-447.	1.6	305
231	Blood Pressure Lowering and Life Expectancy Based on a Markov Model of Cardiovascular Events. Hypertension, 2003, 42, 885-890.	1.3	19
232	Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. Circulation, 2003, 108, 161-165.	1.6	240
233	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 348, 1425-1434.	13.9	771
234	A Randomized Trial of Beta Carotene and Age-Related Cataract in US Physicians. JAMA Ophthalmology, 2003, 121, 372.	2.6	72

#	ARTICLE	IF	CITATIONS
235	Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2084-2091.	3.0	352
236	Development of Predictive Models for Long-Term Cardiovascular Risk Associated With Systolic and Diastolic Blood Pressure. <i>Hypertension</i> , 2002, 39, 105-110.	1.3	116
237	A Prospective Study of Blood Pressure and Risk of Cataract in Men. <i>Annals of Epidemiology</i> , 2001, 11, 104-110.	0.9	34
238	Maternal and Paternal History of Myocardial Infarction and Risk of Cardiovascular Disease in Men and Women. <i>Circulation</i> , 2001, 104, 393-398.	1.6	221
239	Recovery of Ventricular Function after Myocardial Infarction in the Reperfusion Era: The Healing and Early Afterload Reducing Therapy Study. <i>Annals of Internal Medicine</i> , 2001, 134, 451.	2.0	179
240	Zolpidem Use and Hip Fractures in Older People. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1685-1690.	1.3	218
241	Paradoxical Relations of Drug Treatment with Mortality in Older Persons. <i>Epidemiology</i> , 2001, 12, 682-689.	1.2	170
242	Counting Recurrent Events in Cancer Research. <i>Journal of the National Cancer Institute</i> , 2001, 93, 488-489.	3.0	18
243	Academic Detailing to Improve Use of Broad-Spectrum Antibiotics at an Academic Medical Center. <i>Archives of Internal Medicine</i> , 2001, 161, 1897.	4.3	240
244	Histological Pattern of Mandibular Invasion by Oral Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2000, 110, 65-72.	1.1	81
245	Relations of body fat distribution and height with cataract in men. <i>American Journal of Clinical Nutrition</i> , 2000, 72, 1495-1502.	2.2	86
246	Pulse Pressure and Mortality in Older People. <i>Archives of Internal Medicine</i> , 2000, 160, 2765.	4.3	218
247	Systolic and Diastolic Blood Pressure, Pulse Pressure, and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men. <i>Hypertension</i> , 2000, 36, 801-807.	1.3	470
248	Prospective Cohort Study of Antioxidant Vitamin Supplement Use and the Risk of Age-related Maculopathy. <i>American Journal of Epidemiology</i> , 1999, 149, 476-484.	1.6	76
249	Agreement between Drug Treatment Data and a Discharge Diagnosis of Diabetes Mellitus in the Elderly. <i>American Journal of Epidemiology</i> , 1999, 149, 541-549.	1.6	40
250	Definition of Race and Ethnicity in Older People in Medicare and Medicaid. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 730-733.	1.3	37
251	Current and Remote Blood Pressure and Cognitive Decline. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 438.	3.8	233
252	C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction. <i>Circulation</i> , 1998, 97, 2007-2011.	1.6	904

#	ARTICLE	IF	CITATIONS
253	The Effects of Initial Drug Choice and Comorbidity on Antihypertensive Therapy Compliance Results From a Population-Based Study in the Elderly. <i>American Journal of Hypertension</i> , 1997, 10, 697-704.	1.0	246
254	Efficacy of Tympanomastoid Surgery for Control of Infection in Active Chronic Otitis Media. <i>Laryngoscope</i> , 1997, 107, 872-877.	1.1	61
255	Revision Stapedectomy: Intraoperative Findings, Results, and Review of the Literature. <i>Laryngoscope</i> , 1997, 107, 1185-1192.	1.1	75
256	MULTIVARIATE METHODS FOR CLUSTERED ORDINAL DATA WITH APPLICATIONS TO SURVIVAL ANALYSIS. <i>Statistics in Medicine</i> , 1997, 16, 357-372.	0.8	10
257	Prospective Study of Moderate Alcohol Consumption and Risk of Peripheral Arterial Disease in US Male Physicians. <i>Circulation</i> , 1997, 95, 577-580.	1.6	103
258	Ways of measuring rates of recurrent events. <i>BMJ: British Medical Journal</i> , 1996, 312, 364-367.	2.4	177
259	Body Mass Index. <i>JAMA Ophthalmology</i> , 1995, 113, 1131.	2.6	114
260	Adherence to Aspirin in the Prevention of Myocardial Infarction. <i>Archives of Internal Medicine</i> , 1994, 154, 2649.	4.3	66
261	Comparison of alternative regression models for paired binary data. <i>Statistics in Medicine</i> , 1994, 13, 1023-1036.	0.8	40
262	Standardized rates of recurrent outcomes. <i>Statistics in Medicine</i> , 1994, 13, 1781-1791.	0.8	52
263	Risk Factors for Non-Insulin-Dependent Diabetes Mellitus Requiring Treatment in the Elderly. <i>Journal of the American Geriatrics Society</i> , 1994, 42, 1235-1240.	1.3	47
264	Multiple Imputation in Mixture Models for Nonignorable Nonresponse with Follow-ups. <i>Journal of the American Statistical Association</i> , 1993, 88, 984-993.	1.8	121
265	Estimating the Variance of Standardized Rates of Recurrent Events, with Application to Hospitalizations among the Elderly in New England. <i>American Journal of Epidemiology</i> , 1993, 137, 776-786.	1.6	43
266	Modification of Increasing Systolic Blood Pressure in the Elderly during the 1980s. <i>American Journal of Epidemiology</i> , 1993, 138, 365-379.	1.6	20
267	Multiple Imputation in Mixture Models for Nonignorable Nonresponse With Follow-ups. <i>Journal of the American Statistical Association</i> , 1993, 88, 984.	1.8	22
268	Accounting for the Correlation Between Fellow Eyes in Regression Analysis. <i>JAMA Ophthalmology</i> , 1992, 110, 381.	2.6	129
269	Use of Medications by Persons 65 and Over: Data From the Established Populations for Epidemiologic Studies of the Elderly. <i>Journal of Gerontology</i> , 1992, 47, M137-M144.	2.0	218
270	Falls in Elderly Patients With Glaucoma. <i>JAMA Ophthalmology</i> , 1991, 109, 205.	2.6	129

#	ARTICLE	IF	CITATIONS
271	Trends in serum uric acid levels. Arthritis and Rheumatism, 1983, 26, 87-93.	6.7	82
272	A multi-state survival model for time to breast cancer mortality among a cohort of initially disease-free women. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	1